Pharmacogenomics in the Treatment of Multiple Sclerosis: A
Guide to Siponimod
Pharmacogenomics is the study of personalized medicine based on a person's DNA. With a greater understanding of DNA in our modern society, pharmacogenomics is quickly changing the way we treat diseases. A new pharmacogenomic medication being used in the treatment of Multiple Sclerosis (MS) is siponimod (Mayzent). Mayzent has been approved as the first oral medication to treat secondary progressive MS with active disease. This is an important medication that may help to close the gap in therapy for patients who suffer from secondary progressive MS.